BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 27725222)

  • 21. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
    J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble form of LR11 is highly increased in the vitreous fluids of patients with idiopathic epiretinal membrane.
    Hashimoto R; Jiang M; Shiba T; Hiruta N; Takahashi M; Higashi M; Hori Y; Bujo H; Maeno T
    Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):885-891. PubMed ID: 28102455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
    Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
    Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levels of the soluble LDL receptor-relative LR11 decrease in overweight individuals with type 2 diabetes upon diet-induced weight loss.
    Berk KA; Vongpromek R; Jiang M; Schneider WJ; Timman R; Verhoeven AJ; Bujo H; Sijbrands EJ; Mulder MT
    Atherosclerosis; 2016 Nov; 254():67-72. PubMed ID: 27697674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification.
    Kim YR; Kim SJ; Cheong JW; Kim Y; Jang JE; Lee JY; Min YH; Song JW; Yang WI; Kim JS
    Ann Hematol; 2014 Nov; 93(11):1867-77. PubMed ID: 24947797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PET/CT Scanner and Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Diffuse Large B-Cell Lymphoma.
    El Karak F; Bou-Orm IR; Ghosn M; Kattan J; Farhat F; Ibrahim T; Jreige M; El Cheikh J; Haidar M
    PLoS One; 2017; 12(1):e0170299. PubMed ID: 28099514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential utility of serum soluble LR11 as a diagnostic biomarker for intravascular large B-cell lymphoma.
    Kawaguchi T; Ohwada C; Takeuchi M; Shimizu N; Sakaida E; Takeda Y; Sakai S; Tsukamoto S; Yamazaki A; Sugita Y; Higashi M; Fujikawa K; Matsue K; Yokote K; Tamaru J; Bujo H; Nakaseko C
    Leuk Lymphoma; 2014 Oct; 55(10):2391-4. PubMed ID: 24401112
    [No Abstract]   [Full Text] [Related]  

  • 30. The soluble form of LR11 protein is a regulator of hypoxia-induced, urokinase-type plasminogen activator receptor (uPAR)-mediated adhesion of immature hematological cells.
    Nishii K; Nakaseko C; Jiang M; Shimizu N; Takeuchi M; Schneider WJ; Bujo H
    J Biol Chem; 2013 Apr; 288(17):11877-86. PubMed ID: 23486467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wong KK; Ch'ng ES; Loo SK; Husin A; Muruzabal MA; Møller MB; Pedersen LM; Pomposo MP; Gaafar A; Banham AH; Green TM; Lawrie CH
    Exp Mol Pathol; 2015 Dec; 99(3):537-45. PubMed ID: 26341140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study.
    Wolach O; Fraser A; Luchiansky M; Shapiro C; Radnay J; Shpilberg O; Lishner M; Lahav M
    Hematol Oncol; 2015 Mar; 33(1):42-7. PubMed ID: 24470400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor.
    Bairey O; Shacham-Abulafia A; Shpilberg O; Gurion R
    Hematol Oncol; 2016 Dec; 34(4):184-192. PubMed ID: 26052918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
    Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
    Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
    J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
    Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does the presence of tumor-induced cortical bone destruction at CT have any prognostic value in newly diagnosed diffuse large B-cell lymphoma?
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Skeletal Radiol; 2015 May; 44(5):687-94. PubMed ID: 25662178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating soluble LR11, a differentiation regulator for vascular cells, is increased during pregnancy and exaggerated in patients with pre-eclampsia.
    Ishida H; Jiang M; Ebinuma H; Hiruta N; Schneider WJ; Kinoshita T; Bujo H
    Clin Chim Acta; 2019 Oct; 497():172-177. PubMed ID: 31299181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
    Nakamura N; Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Sawada M; Yamada T; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2013 Oct; 91(4):322-31. PubMed ID: 23672298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.